Research
Hormonal
SGLT2 inhibitors provide modest but sustained weight loss and blood pressure reduction, and synergize with other anti-obesity medications.
SGLT2 inhibitors offer modest weight and blood pressure benefits. They are best used in combination with other treatments (like GLP-1 RAs) to synergize benefits, rather than as a standalone primary therapy for obesity-related hypertension.
GoodQualifiesMEDIUM confidence
SGLT2 inhibitors are weak body weight and BP-lowering medications, but clearly synergize the benefits of these medications.
Why this rating
Supported by the text's description of their effects and synergy.
Source
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Aneliya Parvanova et al. · Clinical Kidney Journal · 2025
DOI 10.1093/ckj/sfaf035
narrative_reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Second-generation incretin receptor agonists (GLP-1 RAs like semaglutide and liraglutide, and dual GLP-1/GIP agonist tirzepatide) significantly reduce blood pressure and promote weight loss in obesity-related hypertension, outperforming first-generation anti-obesity drugs.Strong
- Weight loss of at least 5-10% significantly lowers systolic and diastolic blood pressure in obese individuals, and this effect is independent of the specific weight loss strategy used.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →